These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 27433841)
1. β-Lactams against Tuberculosis--New Trick for an Old Dog? Diacon AH; van der Merwe L; Barnard M; von Groote-Bidlingmaier F; Lange C; García-Basteiro AL; Sevene E; Ballell L; Barros-Aguirre D N Engl J Med; 2016 Jul; 375(4):393-4. PubMed ID: 27433841 [No Abstract] [Full Text] [Related]
2. Reappraising the use of β-lactams to treat tuberculosis. Kurz SG; Bonomo RA Expert Rev Anti Infect Ther; 2012 Sep; 10(9):999-1006. PubMed ID: 23106275 [TBL] [Abstract][Full Text] [Related]
3. Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience. Tiberi S; D'Ambrosio L; De Lorenzo S; Viggiani P; Centis R; Sotgiu G; Alffenaar JW; Migliori GB Eur Respir J; 2016 Jan; 47(1):333-6. PubMed ID: 26585427 [No Abstract] [Full Text] [Related]
5. Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate. Gonzalo X; Drobniewski F J Antimicrob Chemother; 2013 Feb; 68(2):366-9. PubMed ID: 23070734 [TBL] [Abstract][Full Text] [Related]
6. Revisiting the β-Lactams for Tuberculosis Therapy with a Compound-Compound Synthetic Lethality Approach. Xiao S; Guo H; Weiner WS; Maddox C; Mao C; Gunosewoyo H; Pelly S; White EL; Rasmussen L; Schoenen FJ; Aubé J; Bishai WR; Lun S Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427291 [TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo efficacy of β-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosis. Solapure S; Dinesh N; Shandil R; Ramachandran V; Sharma S; Bhattacharjee D; Ganguly S; Reddy J; Ahuja V; Panduga V; Parab M; Vishwas KG; Kumar N; Balganesh M; Balasubramanian V Antimicrob Agents Chemother; 2013 Jun; 57(6):2506-10. PubMed ID: 23507276 [TBL] [Abstract][Full Text] [Related]
8. Lessons learned in TB drug discovery: an industrial chemist's perspective. Jiricek J Future Med Chem; 2014; 6(12):1377-80. PubMed ID: 25329194 [No Abstract] [Full Text] [Related]
9. [Clinical and epidemiological characteristics of patients with drug-resistant tuberculosis]. Okulovskaia SS; Gurevich GL; Bogomazova AV Probl Tuberk; 1999; (6):6-8. PubMed ID: 10715945 [TBL] [Abstract][Full Text] [Related]
10. [Accidental discoveries, different mechanisms of action. Active agents against Mycobacterium tuberculosis in clinical application]. Weeken D; Schlitzer M Pharm Unserer Zeit; 2012 Jan; 41(1):35-47. PubMed ID: 22470917 [No Abstract] [Full Text] [Related]
11. [The combination of amoxicillin-clavulanic acid and ofloxacin in the treatment of multidrug-resistant Mycobacterium tuberculosis]. Iwanaga T; Yokota K; Kishikawa R; Ikeda T; Tsurutani H; Hirose T; Nishima S Kekkaku; 1997 Jan; 72(1):9-13. PubMed ID: 9038010 [TBL] [Abstract][Full Text] [Related]
12. Use of beta-lactam/beta-lactamase-inhibitor combinations as antimycobacterial agents. Prabhakaran K; Harris EB; Randhawa B; Adams LB; Williams DL; Hastings RC Microbios; 1993; 76(309):251-61. PubMed ID: 8302203 [TBL] [Abstract][Full Text] [Related]
15. Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis. Cox HS; Sibilia K; Feuerriegel S; Kalon S; Polonsky J; Khamraev AK; Rüsch-Gerdes S; Mills C; Niemann S N Engl J Med; 2008 Nov; 359(22):2398-400. PubMed ID: 19038891 [No Abstract] [Full Text] [Related]
16. New drugs for tuberculosis. Grassi C; Peona V Eur Respir J Suppl; 1995 Sep; 20():714s-718s. PubMed ID: 8590571 [TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo activities of a new lead compound I2906 against Mycobacterium tuberculosis. Lu J; Yue J; Wu J; Luo R; Hu Z; Li J; Bai Y; Tang Z; Xian Q; Zhang X; Wang H Pharmacology; 2010; 85(6):365-71. PubMed ID: 20530976 [TBL] [Abstract][Full Text] [Related]